GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for immunotherapy Jemperli in endometrial cancer and the start of a review in the EU for myelofibrosis ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the complement ...

Subscribe Login Register Log out My Profile Subscriber Services Search EBLADE ENTER-TO-WIN BLADE REWARDS BLADE VAULT / REPRINTS OBITUARIES JOBS CLASSIFIEDS BLADE HOMES HOMES WEEKLY ADS EVENTS CONTACT ...

Learn a different way of saying that something is likely to happen ...